SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

New 24-month HOPE-3 extension data suggesting slower upper-limb decline after patients switched to deramiocel is driving attention. Many traders view the results as supportive of FDA approval, while others stress that the agencys prior statistical and analysis-plan objections leave the outcome uncertain.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances raised full-year revenue outlook, reflecting stronger demand for Amtagvi and Proleukin, is driving the rally, alongside analyst price-target increases. Traders are broadly bullish and cite possible short covering, while some warn of profit-taking or dilution risk after the sharp move; upcoming lung-cancer data is also a focus.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

COMP is drawing attention after a sharp rebound and bullish chart signals, with traders citing its capped token supply and a possible broader DeFi and altcoin recovery. Some also speculate that crypto legislation and claims about Kevin Warshs COMP holdings could help sentiment, while skeptics point to the tokens past underperformance and volatility.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The prolonged selloff to multiyear lows is fueling concern about slowing ad growth, softer advertising demand, and competition from Amazon and automated platforms; traders also point to weak guidance and a reported Safari ad-serving issue. Bears blame management and fear further declines, while bulls argue the cash generation and lower valuation may mean much of the bad news is priced in.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

A DEA judges pause in the broader cannabis rescheduling proceedings, while considering whether to add a government watchdog report to the record, has delayed a closely watched Schedule III catalyst for MSOS. Traders are split between viewing the pause as a procedural setback that could prolong uncertainty and treating it as a temporary delay and buying opportunity.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

The FHFAs move to add VantageScore alongside FICO in the Fannie Mae and Freddie Mac mortgage pricing framework, alongside Rocket Mortgages planned use of VantageScore for eligible loans, has raised concerns that competition could erode FICOs mortgage-scoring dominance and pricing power. Traders are divided between viewing the selloff as an overreaction because lender adoption is not guaranteed and seeing it as a fundamental threat to the companys moat.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Positive Phase 3 results for Vandas Hetlioz in delayed sleep-wake phase disorder are driving attention, with traders focused on the prospect of a label expansion and a potential first FDA-approved treatment for the condition. The reaction is bullish, though some note the small study and that Vanda plans to discuss the data with the FDA before filing for approval.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Reported Lundbeck interest in acquiring Xeris has sparked takeover and possible bidding-war speculation, though no offer or deal is confirmed and Xeris has said it is not for sale. Traders are divided between viewing the report as a potential premium catalyst and questioning whether a transaction is realistic, with some frustrated that the initial spike faded.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings sharp selloff is being discussed amid fears that Kalshi and Polymarket are taking wagering share and that regulatory uncertainty around prediction markets could pressure the sportsbook sector. Traders are split: bears worry about competition and the cost of investing in DraftKings own prediction platform, while bulls point to rising DKeX volumes and continued sportsbook growth.

Direxion Shares ETF Trust - Direxion Daily 20+ Year Treasury Bull 3X Shares

Direxion Daily 20+ Year Treasury Bull 3X Shares

TMF is drawing attention amid a sharp selloff in long-term Treasuries and rising yields, with traders citing inflation concerns and expectations for tighter or higher-for-longer rates. Sentiment is divided: many expect further weakness and are shorting, while others are buying dips or using TMF as a hedge against a recession and eventual rate declines; its daily 3x leverage magnifies the volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$HUBC $muln $ncnc $nvos in same shit club 0.0001 -99.999%